NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.